NovAccess Global Inc. (XSNX)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 2.17 Million USD | 77.8% |
| 2022 | 1.22 Million USD | 865.76% |
| 2021 | 126.86 Thousand USD | -47.75% |
| 2020 | 242.81 Thousand USD | 13.82% |
| 2019 | 213.33 Thousand USD | 6.66% |
| 2018 | 200.01 Thousand USD | -16.05% |
| 2017 | 238.26 Thousand USD | -12.31% |
| 2016 | 271.71 Thousand USD | 82.79% |
| 2015 | 148.64 Thousand USD | -25.77% |
| 2014 | 200.25 Thousand USD | 450.29% |
| 2013 | 36.39 Thousand USD | -90.14% |
| 2012 | 368.93 Thousand USD | -5.48% |
| 2011 | 390.34 Thousand USD | 52.18% |
| 2010 | 256.49 Thousand USD | 447.58% |
| 2009 | -73.79 Thousand USD | 96.91% |
| 2008 | -2.38 Million USD | -34.7% |
| 2007 | -1.77 Million USD | 58.8% |
| 2006 | -4.3 Million USD | -738.62% |
| 2005 | 674.13 Thousand USD | 1966.42% |
| 2004 | -36.11 Thousand USD | -1439.6% |
| 2003 | -2346.00 USD | -101.2% |
| 2002 | 195.72 Thousand USD | 1.75% |
| 2001 | 192.35 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 2.18 Million USD | 0.34% |
| 2024 Q3 | 33.2 Thousand USD | -2.83% |
| 2024 Q2 | 2.15 Million USD | -1.42% |
| 2023 Q3 | 1.84 Million USD | 5.11% |
| 2023 Q2 | 1.75 Million USD | 17.07% |
| 2023 FY | 2.17 Million USD | 77.8% |
| 2023 Q4 | 2.17 Million USD | 17.99% |
| 2023 Q1 | 1.5 Million USD | 22.46% |
| 2022 Q2 | 682.63 Thousand USD | 16.12% |
| 2022 Q3 | 649.82 Thousand USD | -4.81% |
| 2022 Q4 | 1.22 Million USD | 88.55% |
| 2022 FY | 1.22 Million USD | 865.76% |
| 2022 Q1 | 587.88 Thousand USD | 363.38% |
| 2021 Q1 | 212.32 Thousand USD | -12.56% |
| 2021 Q2 | 224.21 Thousand USD | 5.6% |
| 2021 Q3 | 198.09 Thousand USD | -11.65% |
| 2021 Q4 | 126.86 Thousand USD | -35.96% |
| 2021 FY | 126.86 Thousand USD | -47.75% |
| 2020 Q1 | 5271.00 USD | -97.53% |
| 2020 Q4 | 242.81 Thousand USD | 11.72% |
| 2020 Q2 | 103.43 Thousand USD | 1862.4% |
| 2020 Q3 | 217.34 Thousand USD | 110.12% |
| 2020 FY | 242.81 Thousand USD | 13.82% |
| 2019 Q1 | 152.51 Thousand USD | -23.75% |
| 2019 Q2 | 194.02 Thousand USD | 27.22% |
| 2019 Q4 | 213.33 Thousand USD | 33.41% |
| 2019 FY | 213.33 Thousand USD | 6.66% |
| 2019 Q3 | 159.9 Thousand USD | -17.58% |
| 2018 Q1 | 229.59 Thousand USD | -3.64% |
| 2018 Q4 | 200.01 Thousand USD | 12.49% |
| 2018 Q3 | 177.81 Thousand USD | -19.47% |
| 2018 Q2 | 220.8 Thousand USD | -3.83% |
| 2018 FY | 200.01 Thousand USD | -16.05% |
| 2017 Q3 | 175.36 Thousand USD | -7.56% |
| 2017 FY | 238.26 Thousand USD | -12.31% |
| 2017 Q4 | 238.26 Thousand USD | 35.87% |
| 2017 Q2 | 189.7 Thousand USD | 35.38% |
| 2017 Q1 | 140.13 Thousand USD | -48.43% |
| 2016 Q4 | 271.71 Thousand USD | 7.36% |
| 2016 Q1 | 218.11 Thousand USD | 46.73% |
| 2016 Q2 | 202.18 Thousand USD | -7.3% |
| 2016 Q3 | 253.08 Thousand USD | 25.17% |
| 2016 FY | 271.71 Thousand USD | 82.79% |
| 2015 FY | 148.64 Thousand USD | -25.77% |
| 2015 Q4 | 148.64 Thousand USD | -26.04% |
| 2015 Q3 | 200.97 Thousand USD | 18.73% |
| 2015 Q2 | 169.26 Thousand USD | -34.25% |
| 2015 Q1 | 257.42 Thousand USD | 28.55% |
| 2014 Q4 | 200.25 Thousand USD | 22.83% |
| 2014 FY | 200.25 Thousand USD | 450.29% |
| 2014 Q1 | 140.97 Thousand USD | 287.38% |
| 2014 Q3 | 163.04 Thousand USD | -10.66% |
| 2014 Q2 | 182.49 Thousand USD | 29.46% |
| 2013 Q1 | 213.33 Thousand USD | -42.18% |
| 2013 Q4 | 36.39 Thousand USD | -83.94% |
| 2013 FY | 36.39 Thousand USD | -90.14% |
| 2013 Q3 | 226.58 Thousand USD | 13.75% |
| 2013 Q2 | 199.19 Thousand USD | -6.63% |
| 2012 Q2 | 329.76 Thousand USD | -3.17% |
| 2012 Q4 | 368.93 Thousand USD | 7.23% |
| 2012 FY | 368.93 Thousand USD | -5.48% |
| 2012 Q3 | 344.05 Thousand USD | 4.33% |
| 2012 Q1 | 340.56 Thousand USD | -12.75% |
| 2011 Q1 | 409.48 Thousand USD | 59.64% |
| 2011 Q2 | 312.43 Thousand USD | -23.7% |
| 2011 Q3 | 309.29 Thousand USD | -1.01% |
| 2011 Q4 | 390.34 Thousand USD | 26.21% |
| 2011 FY | 390.34 Thousand USD | 52.18% |
| 2010 Q3 | -15.59 Thousand USD | 88.9% |
| 2010 FY | 256.49 Thousand USD | 447.58% |
| 2010 Q2 | -140.52 Thousand USD | -177.66% |
| 2010 Q4 | 256.49 Thousand USD | 1744.86% |
| 2010 Q1 | 180.95 Thousand USD | 345.21% |
| 2009 Q1 | -1.55 Million USD | 34.91% |
| 2009 Q2 | -957.38 Thousand USD | 38.44% |
| 2009 FY | -73.79 Thousand USD | 96.91% |
| 2009 Q4 | -73.79 Thousand USD | 87.77% |
| 2009 Q3 | -603.35 Thousand USD | 36.98% |
| 2008 Q1 | -2.18 Million USD | -23.37% |
| 2008 FY | -2.38 Million USD | -34.7% |
| 2008 Q4 | -2.38 Million USD | 47.81% |
| 2008 Q3 | -4.57 Million USD | -32.03% |
| 2008 Q2 | -3.46 Million USD | -58.44% |
| 2007 Q2 | -2.4 Million USD | 34.96% |
| 2007 Q1 | -3.69 Million USD | 14.24% |
| 2007 Q4 | -1.77 Million USD | -30.06% |
| 2007 FY | -1.77 Million USD | 58.8% |
| 2007 Q3 | -1.36 Million USD | 43.21% |
| 2006 Q4 | -4.3 Million USD | -35.55% |
| 2006 Q2 | 30.74 Thousand USD | -98.04% |
| 2006 Q3 | -3.17 Million USD | -10431.23% |
| 2006 Q1 | 1.57 Million USD | 133.16% |
| 2006 FY | -4.3 Million USD | -738.62% |
| 2005 Q4 | 674.13 Thousand USD | 18722.4% |
| 2005 Q1 | -329.32 Thousand USD | -811.77% |
| 2005 Q2 | -155.47 Thousand USD | 52.79% |
| 2005 FY | 674.13 Thousand USD | 1966.42% |
| 2005 Q3 | -3620.00 USD | 97.67% |
| 2004 FY | -36.11 Thousand USD | -1439.6% |
| 2004 Q2 | 7907.00 USD | 68.48% |
| 2004 Q3 | -64.77 Thousand USD | -919.2% |
| 2004 Q4 | -36.11 Thousand USD | 44.24% |
| 2004 Q1 | 4693.00 USD | 300.04% |
| 2003 Q2 | 195.72 Thousand USD | 0.0% |
| 2003 Q1 | 195.72 Thousand USD | 0.0% |
| 2003 FY | -2346.00 USD | -101.2% |
| 2003 Q3 | 195.72 Thousand USD | 0.0% |
| 2003 Q4 | -2346.00 USD | -101.2% |
| 2002 Q2 | 195.15 Thousand USD | 0.13% |
| 2002 Q1 | 194.9 Thousand USD | 1.32% |
| 2002 Q3 | 195.72 Thousand USD | 0.29% |
| 2002 Q4 | 195.72 Thousand USD | 0.0% |
| 2002 FY | 195.72 Thousand USD | 1.75% |
| 2001 FY | 192.35 Thousand USD | 0.0% |
| 2001 Q2 | 234.1 Thousand USD | -14.27% |
| 2001 Q3 | 234.1 Thousand USD | 0.0% |
| 2001 Q4 | 192.35 Thousand USD | -17.83% |
| 2001 Q1 | 273.07 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | 166395.038% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 61.432% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 94.909% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 972.713% |
| Rebus Holdings, Inc. | 305 Thousand USD | -614.251% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 134.554% |
| Qrons Inc. | 351.42 Thousand USD | -519.891% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 622.36 Thousand USD | -250.031% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 94.984% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 10774.564% |
| Skye Bioscience, Inc. | -5.72 Million USD | 138.076% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 86.18% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 47.099% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -442.11% |
| SQZ Biotechnologies Company | -36.23 Million USD | 106.012% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 2.844% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | -134.954% |
| Mesoblast Limited | 55.85 Million USD | 96.1% |
| Marizyme, Inc. | 18.56 Million USD | 88.268% |
| Genus plc | 190.6 Million USD | 98.857% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 2.566% |
| Pharming Group N.V. | 109.8 Million USD | 98.016% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | -153.239% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | -79.462% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | -220.363% |
| ContraFect Corporation | -6.02 Million USD | 136.151% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -1518.004% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | -88.542% |
| IMV Inc. | 7.67 Million USD | 71.6% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 60.405% |
| MultiCell Technologies, Inc. | 90.04 USD | -2419341.359% |
| ONE Bio Corp. | 9.04 Million USD | 75.902% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 396.802% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 83.173% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | -59.248% |
| Q BioMed Inc. | 4.06 Million USD | 46.343% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 92.87% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | -116.178% |
| Biomind Labs Inc. | 711.4 Thousand USD | -206.221% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 96.402% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | -8.956% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 82.989% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -505.617% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -1458.228% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -10865.244% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 1.068% |
| GB Sciences, Inc. | 1.74 Million USD | -24.675% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 1285.314% |
| HST Global, Inc. | 96.79 Thousand USD | -2150.643% |
| CSL Limited | 10.52 Billion USD | 99.979% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -956.394% |
| Halberd Corporation | 144.72 Thousand USD | -1405.286% |
| Enzolytics Inc. | 981.65 Thousand USD | -121.917% |
| Agentix Corp. | 37.63 Thousand USD | -5689.017% |
| Resverlogix Corp. | 6.45 Million USD | 66.231% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 423.652% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -2.02 Billion USD | 100.107% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 104.634% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 69.191% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 19.573% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 124.644% |
| AVAX Technologies, Inc. | -5.9 Million USD | 136.903% |
| Zenith Capital Corp. | 10.06 Thousand USD | -21546.115% |
| Genscript Biotech Corporation | -1.06 Billion USD | 100.205% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -986.885% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 8.699% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -1224.222% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 11992.483% |
| Kadimastem Ltd | -253.1 Thousand USD | 960.706% |
| Helix BioMedix, Inc. | -2.57 Million USD | 184.764% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 89.256% |
| BioStem Technologies, Inc. | 4.47 Million USD | 51.287% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -982.446% |
| LadRx Corporation | -2.03 Million USD | 206.973% |
| Cell Source, Inc. | 9.23 Million USD | 76.403% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -242.975% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -242.975% |
| Affymax, Inc. | -5.59 Million USD | 138.922% |
| Itoco Inc. | 228.3 Thousand USD | -854.191% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -1501.942% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 56.053% |
| Mobile Lads Corp. | 484.23 Thousand USD | -349.88% |
| CytoDyn Inc. | 20.26 Million USD | 89.249% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 336802.473% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 23604.371% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 71.73% |
| SYBLEU INC | 473.71 Thousand USD | -359.869% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 51.123% |
| International Stem Cell Corporation | 2.59 Million USD | 15.889% |
| Bioxytran, Inc. | 1.89 Million USD | -14.722% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -3390.403% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 0.112% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 36.562% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 74.53% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | -181.963% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 274.277% |
| Neutra Corp. | 52.18 Thousand USD | -4074.344% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 187.524% |
| PureTech Health plc | -167.19 Million USD | 101.303% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 989.503% |
| IXICO plc | -4.44 Million USD | 149.014% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 83.52% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 96.028% |
| CSL Limited | 10.52 Billion USD | 99.979% |
| Cellectis S.A. | -43.81 Million USD | 104.972% |